All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
POLARIX: How does MYC and BCL2 expression impact outcomes post frontline treatment with PV in DLBCL?
Featured
During the EHA 2022 Congress, the Lymphoma Hub spoke with Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US. We asked, POLARIX trial: How does MYC and BCL2 expression impact outcomes post frontline treatment with polatuzumab vedotin (PV) in diffuse large B-cell lymphoma (DLBCL).
POLARIX: How does MYC and BCL2 expression impact outcomes post frontline treatment with PV in DLBCL?
Salles discusses the activity of the combination polatuzumab vedotin + rituximab-CHOP in patients with DLBCL, and some chromosomal abnormalities. Salles outlines the consequences of BCL2 overexpression on treatment outcomes, and the improvement that this combination has shown for this patient group.
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox